Cargando…
Safety Evaluation of the MiniMed 670G System in Children 7–13 Years of Age with Type 1 Diabetes
Objective: To evaluate the safety of in-home use of the MiniMed™ 670G system with SmartGuard™ technology in children with type 1 diabetes (T1D). Methods: Participants (N = 105, ages 7–13 years, mean age 10.8 ± 1.8 years) were enrolled at nine centers (eight in the United States and one in Israel) an...
Autores principales: | Forlenza, Gregory P., Pinhas-Hamiel, Orit, Liljenquist, David R., Shulman, Dorothy I., Bailey, Timothy S., Bode, Bruce W., Wood, Michael A., Buckingham, Bruce A., Kaiserman, Kevin B., Shin, John, Huang, Suiying, Lee, Scott W., Kaufman, Francine R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350071/ https://www.ncbi.nlm.nih.gov/pubmed/30585770 http://dx.doi.org/10.1089/dia.2018.0264 |
Ejemplares similares
-
Glycemic outcomes of children 2–6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial
por: Forlenza, Gregory P., et al.
Publicado: (2022) -
Medtronic MiniMed 670G Hybrid Closed-Loop System
por: Knebel, Tory, et al.
Publicado: (2019) -
Medtronic MiniMed 670G Auto Mode: Implications for Clinical Practice
por: Dos Santos-Marinho, Jeanne, et al.
Publicado: (2021) -
Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor
por: Cordero, Toni L., et al.
Publicado: (2023) -
The Effectiveness of Virtual Training on the MiniMed™ 670G System in People with Type 1 Diabetes During the COVID-19 Pandemic
por: Vigersky, Robert A., et al.
Publicado: (2021)